AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse
Germany · 556 open tenders · 1,097 documented awards
Current tenders
Framework Agreement Green Garden
Deadline 16 Oct ·
Framework Agreement Green Garden
1.723.000 €Deadline 16 Oct ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a (8)/130c (1) SGB V for medicinal products containing the active substance guselkumab (L04AC16) within the framework of a so-called open-house model.
Deadline 31 Oct ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a (8)/130c (1) SGB V for medicinal products containing the active substance Cetrorelix (H01CC02) within the framework of a so-called Open-House Model.
Deadline 31 Oct ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance sodium levothyroxine (H03AA01) within the framework of a so-called open-house model.
Deadline 31 Oct ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active ingredient Fluorouracil, combinations (D11AF55) within the framework of a so-called open-house model.
Deadline 31 Oct ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance Fluorouracil, combinations (D11AF55) within the framework of a so-called open-house model.
Deadline 31 Oct ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a(8)/130c(1) SGB V for medicinal products containing the active substance guselkumab (L04AC16) within the framework of a so-called open-house model.
Deadline 31 Oct ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance levothyroxine sodium (H03AA01) within the framework of a so-called open-house model.
Deadline 31 Oct ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance Cetrorelix (H01CC02) within the framework of a so-called Open-House model.
Deadline 31 Oct ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance peginterferon beta-1a (L03AB13) within the framework of a so-called open-house model.
Deadline 30 Nov ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a (8)/130c (1) SGB V for medicinal products containing the active substance pegfilgrastim (L03AA13) within the framework of a so-called open-house model.
Deadline 30 Nov ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance dornase alfa (R05CB13) within the framework of a so-called open-house model.
Deadline 30 Nov ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active ingredient acetylsalicylic acid (B01AC06) within the framework of a so-called open-house model.
Deadline 30 Nov ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active ingredient minoxidil (C02DC01) within the framework of a so-called open-house model.
Deadline 30 Nov ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance Nilotinib (L01EA03), excluding administration dispersed in applesauce (pureed apple) within the framework of a so-called open-house model.
Deadline 30 Nov ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance dornase alfa (R05CB13) within the scope of a so-called open-house model.
Deadline 30 Nov ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products with the active ingredient acetylsalicylic acid (B01AC06) within the framework of a so-called open-house model.
Deadline 30 Nov ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products with the active ingredient pegfilgrastim (L03AA13) within the framework of a so-called open-house model.
Deadline 30 Nov ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance minoxidil (C02DC01) within the framework of a so-called open-house model.
Deadline 30 Nov ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance nilotinib (L01EA03), excluding administration dispersed in applesauce (pureed apple) within the framework of a so-called open-house model.
Deadline 30 Nov ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active ingredient peginterferon beta-1a (L03AB13) within the framework of a so-called open-house model.
Deadline 30 Nov ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance tadalafil (G04BE08), medicinal products only with the indication benign prostatic syndrome within the framework of a so-called open-house model.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a (8)/130c (1) SGB V for medicinal products containing the active substance ritonavir (J05AE03) within the framework of a so-called open-house model.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance Tientine (A16AX12) within the framework of a so-called Open-House Model.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a (8)/130c (1) SGB V for medicinal products containing the active substance iron(III) oxide-saccharose complex (B03AC02) within the framework of a so-called open-house model.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance ritonavir (J05AE03) within the framework of a so-called open-house model.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance tientine (A16AX12) within the framework of a so-called open-house model.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance iron(III) oxide-sucrose complex (B03AC02) within the framework of a so-called open-house model.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance tadalafil (G04BE08), exclusively medicinal products indicated for benign prostatic syndrome within the framework of a so-called open-house model.
Deadline 31 Dec ·
Purchasing rhythm
Awards per year — who knows the rhythm prepares before the notice appears.
2018245
2019331
2020316
2021345
2022359
2023450
2024561
2025550
2026295
Clement What the numbers say about this buyer
- 37% of the bids received came from other countries (27 procedures with a bid mix) — all bidders, not just the winners. Country: 3%.n = 27
- 68% of this buyer's awards went to companies that had already won here before (987 awards since 2018, spread over 320 companies). That is well above the national norm (45%) — newcomers have a harder time here than elsewhere.n = 987 awards since 2018
- The award came in at a median 56% of the estimated value (14 awards with both estimate and value) — pricing at the estimate is usually too high here. Country: 86%.n = 14
- The median procedure drew just one bid (963 procedures with a bid count); 88% ended with a single bidder. Country: median 3.1 bids.n = 963
- 90% of the bids received came from small and medium-sized enterprises (27 procedures with a bid mix). Country: 75%.n = 27
- Across 247 procedures with structured selection criteria, this buyer most often required: Security of supply required (233 of 247), Quality management (10 of 247), Special authorisation or membership required (2 of 247), Professional register enrolment (2 of 247).n = 247
- Not one of the 987 awards with a known winner country has gone to a foreign company so far. National average: 1%.n = 987
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 04/10/2026.
Expected next awards
From the rhythm of past awards per sector — an expectation, not an announcement. Hit rate so far: 26% of 11,200 closed expectation windows produced a notice.
- Mar 2027Furniture & furnishings
about every 7 months · 18 awards · last Aug 2026 to sumsum OfficeMöbility Kirstin Hoppelshäuser - Jan 2028Petroleum & fuels
about every 20 months · 4 awards · last May 2026 to Walter Fritz Deutsche Gesellschaft für Energieversorgung mbH
Who has won here before
| Company | Awards | Period |
|---|---|---|
| axicorp Pharma B.V. · EC Den Haag | 32 | 2017–2022 |
| Aliud Pharma GmbH · Laichingen | 28 | 2017–2023 |
| Abacus Medicine A/S · Kopenhagen | 27 | 2018–2023 |
| kohlpharma GmbH · Merzig | 26 | 2017–2023 |
| EurimPharm Arzneimittel GmbH · Saaldorf-Surheim | 25 | 2019–2023 |
| CC Pharma GmbH · Densborn | 25 | 2017–2023 |
| betapharm Arzneimittel GmbH · Augsburg | 24 | 2017–2022 |
| Orifarm GmbH · Leverkusen | 23 | 2018–2022 |
| Hexal AG · Holzkirchen | 19 | 2017–2023 |
| Haemato Pharm GmbH · Schönefeld | 17 | 2017–2022 |
From 18.0M documented awards · regular winners know this buyer's requirements — that is your competition.